Jaskra złośliwa: nowe poglądy na etiopatogenezę i postępowanie

• Authors: Dorota Pożarowska , Tomasz Żarnowski

Title variants

EN

Malignant glaucoma: new views on its etiopathogenesis and management

• Languages of publication: PL

Abstracts

PL

Jaskra złośliwa jest rzadkim, ale poważnym powikłaniem operacji wewnątrzgałkowych. Najczęściej pojawia się po penetrujących zabiegach przeciwjaskrowych, ale może także wystąpić po każdej procedurze wewnątrzgałkowej. Jej obecność niosła ze sobą złą prognozę i bardzo wysokie ryzyko bolesnej ślepoty. Istotę choroby stanowi nieprawidłowy przepływ cieczy wodnistej w kierunku ciała szklistego, który doprowadza do przemieszczenia przepony soczewkowo-tęczówkowej lub tęczówkowo-szklistkowej ku przodowi i do zamknięcia kąta przesączania. Celem leczenia jest przywrócenie prawidłowego przepływu cieczy wodnistej i poprawa stosunków anatomicznych w gałce ocznej. W leczeniu stosowane są metody farmakologiczne (leki hamujące wytwarzanie cieczy wodnistej, cykloplegiki, leki osmotycznie czynne), techniki laserowe i chirurgiczne. Dzięki wprowadzeniu nowych technik operacyjnych, jak zonulokapsulohialoidowitrektomia, rokowanie w przypadku wystąpienia tego powikłania znacząco się poprawiło.

EN

Malignant glaucoma is a rare but serious complication of intraocular surgery. Most frequently it occurs after penetrating antiglaucoma procedures, but may also be present after intraocular procedures. Its presence ia associated with very bad prognosis with high risk of painful blindness. The essence of this disease is abnormal aqueous flow to vitreous cavity with leads to the forward displacement of iridolenticular or iridovitreal diaphragm and anterior angle closure. The crucial aim of treatment is to reverse abnormal aqueous flow and improve anterior segment anatomical relationships. Medical therapy (aqueous suppressants, cycloplegics, hyperosmotic agents), lasers techniques and surgery are used for this treatment. Due to the development of new surgical techniques the prognosis for malignant glaucoma has significantly improved.

Keywords

EN

blok rzęskowo-soczewkowy; blok tęczówkowo-rzęskowo-szklistkowy; jaskra złośliwa; zespół nieprawidłowego przepływu cieczy wodnistej; zonulokapsulohialoidowitrektomia

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2019
• Volume: 6
• Issue: 3
• Pages: 160-167

Contributors

author

Dorota Pożarowska

• Klinika Diagnostyki i Mikrochirurgii Jaskry, Uniwersytet Medyczny w Lublinie

author

Tomasz Żarnowski

• Klinika Diagnostyki i Mikrochirurgii Jaskry, Uniwersytet Medyczny w Lublinie

References

• 1. Krix-Jachym K, Żarnowski T, Rękas M. Risk Factors of Malignant Glaucoma Occurrence after Glaucoma Surgery. J Ophthalmol 2017; 2017: 9616738.
• 2. Graefe A. Beiträge zur Pathologie und Therapie des Glaucoms. Albrecht von Graefes Archiv für Ophthalmologie 1869; 15: 108-252.
• 3. Grzybowski A, Kanclerz P. Acute and chronic fluid misdirection syndrome: pathophysiology and treatment. Graefes Arch Clin Exp Ophthalmol 2018; 256(1): 135-154.
• 4. Foreman-Larkin J, Netland PA, Salim S. Clinical Management of Malignant Glaucoma. J Ophthalmol 2015; 2015: 283707. DOI: 10.1155/2015/283707. Epub 2015 Dec 24.
• 5. Balekudaru S, Choudhari NS, Rewri P, et al. Surgical management of malignant glaucoma: a retrospective analysis of fifty eight eyes. Eye (Lond). 2017; 31(6): 947-955.
• 6. Burgansky-Eliash Z, Ishikawa H, Schuman JS. Hypotonous malignant glaucoma: aqueous misdirection with low intraocular pressure. Ophthalmic Surg Lasers Imaging 2008; 39(2): 155-159.
• 7. Sahoo NK, Balijepalli P, Singh SR, et al. Retina and glaucoma: surgical complications. Int J Retina Vitreous 2018; 4: 29.
• 8. Kaplowitz K, Yung E, Flynn R, et al. Current concepts in the treatment of vitreous block, also known as aqueous misdirection. Surv Ophthalmol 2015; 60(3): 229-241.
• 9. Rękas M, Krix-Jachym K, Żarnowski T. Evaluation of the Effectiveness of Surgical Treatment of Malignant Glaucoma in Pseudophakic Eyes through Partial PPV with Establishment of Communication between the Anterior Chamber and the Vitreous Cavity. J Ophthalmol 2015; 2015: 873124.
• 10. Greenfield DS, Tello C, Budenz DL, et al. Aqueous misdirection after glaucoma drainage device implantation. Ophthalmology 1999; 106(5): 1035-1040.
• 11. Shahid H, Salmon JF. Malignant glaucoma: a review of the modern literature. J Ophthalmol 2012; 2012: 852659.
• 12. Ghoraba HH, Ghali AA, Mansour HO. Aqueous misdirection following pars planavitrectomy and silicone oil injection. Clin Ophthalmol 2015; 9: 903-906.
• 13. Varma DK, Belovay GW, Tam DY, et al. Malignant glaucoma after cataract surgery. J Cataract Refract Surg 2014; 40(11): 1843-1849.
• 14. Francis BA, Babel D. Malignant glaucoma (aqueous misdirection) after pars planavitrectomy. Ophthalmology 2000; 107(7): 1220-1222.
• 15. Montolío Marzo S, Lanzagorta Aresti A, Davó Cabrera JM, et al. Malignant glaucoma after XEN45 implant. Arch Soc Esp Oftalmol 2019; 94(3): 134-137.
• 16. Senthil S, Choudhari NS, Vaddavalli PK, et al. Etiology and Management of Raised Intraocular Pressure following Posterior Chamber Phakic Intraocular Lens Implantation in Myopic Eyes. PLoS One 2016; 11(11): e0165469.
• 17. Arya SK, Sonika, Kochhar S, et al. Malignant glaucoma as a complication of Nd:YAG laser posterior capsulotomy. Ophthalmic Surg Lasers Imaging 2004; 35(3): 248-250.
• 18. Greenfield JA, Smiddy WE, Greenfield DS. Malignant Glaucoma After Laser Peripheral Iridotomy. J Glaucoma 2019; 28(3): e44-e45.
• 19. Premsenthil M, Salowi MA, Siew CM, et al. Spontaneous malignant glaucoma in a patient with patent peripheral iridotomy. BMC Ophthalmol 2012; 12: 64.
• 20. Brooks AM, Harper CA, Gillies WE. Occurrence of malignant glaucoma after laser iridotomy. Br J Ophthalmol 1989; 73(8): 617-620.
• 21. Harbour JW, Rubsamen PE, Palmberg P. Pars planavitrectomy in the management of phakic and pseudophakic malignant glaucoma. Arch Ophthalmol 1996; 114(9): 1073-1078.
• 22. Chandler PA. Malignant glaucoma. Am J Ophthalmol 1951; 34(7): 993-1000.
• 23. Faucher A, Hasanee K, Rootman DS. Phacoemulsification and intraocular lens implantation in nanophthalmic eyes: report of a medium-size series. J Cataract Refract Surg 2002; 28(5): 837-842.
• 24. Żarnowski T, Wilkos-Kuc A, Tulidowicz-Bielak M, et al. Efficacy and safety of a new surgical method to treat malignant glaucoma in pseudophakia. Eye (Lond) 2014; 28(6): 761-764. DOI: 10.1038/eye.2014.53. Epub2014 Mar 14.
• 25. Sharma A, Sii F, Shah P, et al. Vitrectomy-phacoemulsification-vitrectomy for the management of aqueous misdirection syndromes in phakic eyes. Ophthalmology 2006; 113(11): 1968-1973.
• 26. Debrouwere V, Stalmans P, Van Calster J, et al. Outcomes of different management options for malignant glaucoma: a retrospective study. Graefes Arch Clin Exp Ophthalmol 2012; 250(1): 131-41.
• 27. Prata TS, Dorairaj S, De Moraes CG, et al. Is preoperative ciliary body and iris anatomical configuration a predictor of malignant glaucoma development? Clin Exp Ophthalmol 2013; 41(6): 541-545.
• 28. He F, Qian Z, Lu L, et al. Clinical efficacy of modified partial pars plana vitrectomy combined with phacoemulsification for malignant glaucoma. Eye (Lond) 2016; 30(8): 1094-1100.
• 29. Wang Z, Huang J, Lin J, et al. Quantitative measurements of the ciliary body in eyes with malignant glaucoma after trabeculectomy using ultrasound biomicroscopy. Ophthalmology 2014; 121(4): 862-869.
• 30. Razeghinejad MR, Amini H, Esfandiari H. Lesser anterior chamber dimensions in women may be a predisposing factor for malignant glaucoma. Med Hypotheses 2005; 64(3): 572-574.
• 31. Heindl LM, Koch KR, Cursiefen C, et al. Optical coherence tomography and ultrasound biomicroscopy in the management of pseudophakic malignant glaucoma. Graefes Arch Clin Exp Ophthalmol 2013; 251(9): 2261-2263.
• 32. Quigley HA, Friedman DS, Congdon NG. Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma 2003; 12(2): 167-180.
• 33. Quigley HA. Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson Memorial Lecture. Am J Ophthalmol 2009; 148(5): 657-669.e1.
• 34. Chen X, Guo X, Xu X, et al. Is Thicker Choroid a Risk Factor for Malignant Glaucoma? Ophthalmic Res 2018; 60(3): 161-168.
• 35. Trope GE, Pavlin CJ, Bau A, et al. Malignant glaucoma. Clinical and ultrasound biomicroscopic features. Ophthalmology 1994; 101(6): 1030-1035.
• 36. Liebmann JM, Weinreb RN, Ritch R. Angle-closure glaucoma associated with occult annular ciliary body detachment. Arch Ophthalmol 1998; 116(6): 731-775.
• 37. Wirbelauer C, Karandish A, Häberle H, et al. Optical coherence tomography in malignant glaucoma following filtration surgery. Br J Ophthalmol 2003; 87(8): 952-955.
• 38. Wu ZH, Wang YH, Liu Y. Management strategies in malignant glaucoma secondary to antiglaucoma surgery. Int J Ophthalmol. 2016; 9(1): 63-68.
• 39. Chandler PA, Simmons RJ, Grant WM. Malignant glaucoma. Medical and surgical treatment. Am J Ophthalmol 1968; 66(3): 495-502.
• 40. Pakravan M, Esfandiari H, Amouhashemi N, et al. Mini-vitrectomy; a Simple Solution to a Serious Condition. J Ophthalmic Vis Res 2018; 13(3): 231-235.
• 41. Tsai JC, Barton KA, Miller MH, et al. Surgical results in malignant glaucoma refractory to medical or laser therapy. Eye (Lond) 1997; 11(Pt 5): 677-681.
• 42. Chandler PA. A New Operation for Malignant Glaucoma: a Preliminary Report. Trans Am Ophthalmol Soc 1964; 62: 408-424.
• 43. Dave P, Rao A, Senthil S, et al. Recurrence of aqueous misdirection following pars plana vitrectomy in pseudophakic eyes. BMJ Case Rep 2015; 2015. pii: bcr2014207961.
• 44. Little BC, Hitchings RA. Pseudophakic malignant glaucoma: Nd:YAG capsulotomy as a primary treatment. Eye (Lond) 1993; 7(Pt 1): 102-104.
• 45. Madgula IM, Anand N. Long-term follow-up of zonulo-hyaloido-vitrectomy for pseudophakic malignant glaucoma. Indian J Ophthalmol 2014; 62(12): 1115-1120.
• 46. Lois N, Wong D, Groenewald C. New surgical approach in the management of pseudophakic malignant glaucoma. Ophthalmology 2001; 108(4): 780-783.
• 47. Tang J, Du E, Li X. Combined Surgical Techniques for the Management of Malignant Glaucoma. J Ophthalmol 2018; 2018: 9189585.
• 48. Meng L, Wei W, Li Y, et al. 25-Gauge pars plana vitrectomy for ciliary block (malignant) glaucoma. Int Ophthalmol 2015; 35(4): 487-493.
• 49. Chaudhry NA, Flynn HW Jr, Murray TG, et al. Pars plana vitrectomy during cataract surgery for prevention of aqueous misdirection in high-risk fellow eyes. Am J Ophthalmol 2000; 129(3): 387-388.
• 50. Yu J, Chen X, Zhou D, et al. Clinical Efficacy of Ciliary Ring Incision Combined with Modified Partial Pars Plana Vitrectomy for Malignant Glaucoma. Med Sci Monit 2018; 24: 3916-3921.
• 51. Rani PK, Gulati I, Rao HL, et al. 25g pars plana vitrectomy and irido-zonulo-hyaloido-vitrectomy in the management of malignant glaucoma in phakic eyes following trabeculectomy. Retin Cases Brief Rep 2018; 12(1): 33-35.
• 52. Graber M, Khoueir Z, Beauchet A, et al. High intensity focused ultrasound as first line treatment in patients with chronic angle closure glaucoma at risk for malignant glaucoma. J Fr Ophtalmol 2017; 40(4): 264-269.
• 53. Thompson AC, Challa P. Prophylactic anterior vitrectomy during cataract surgery in eyes at increased risk for aqueous misdirection. Am J Ophthalmol Case Rep 2018; 12: 24-27.
• 54. Pathak Ray V, Gulati I, Choudhari N. Intra-Operative Ostial Irido-Zonulo-Hyaloido-Vitrectomy with Primary Posterior Capsulectomy for Prevention of Post-Operative Aqueous Misdirection in Combined Phaco-Trabeculectomy in Primary Angle Closure Glaucoma. Curr Eye Res 2019: 1-4.

• Document Type: article